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VerapamilAbstract Background: The aim of this study was to evaluate the effects of adding two different
doses (2.5 mg or 5 mg) of verapamil to lidocaine ketamine (0.5 mg/kg) during Intravenous Regional
Anesthesia (IVRA) compared with lidocaine with ketamine alone.
Methods: Seventy-ﬁve patients, aged 18–50 years, ASA physical status I and II undergoing elective
hand or forearm surgery under Bier’s Block lasting one to one and half hours were included in this
randomized controlled double-blind study. Patients were divided into three groups, 25 each to receive
either group (I, control group) received 40 ml of 0.5% Lidocaine plus ketamine (0.5 mg/kg), group (II)
received as group I plus verapamil 2.5 mg or group (III) received as group I plus verapamil 5 mg for
IVRA. Postoperative assessment of block characteristics, sedation, pain, ﬁrst time for rescue analge-
sia, hemodynamic changes and side effects were evaluated over a period of 12 h.
Results: Block characteristics were signiﬁcant in groups II and III compared with group I. There
were signiﬁcant hemodynamic changes, sedation score, pain score and delayed ﬁrst request for anal-
gesics postoperatively in groups (II) and (III) compared to group (I) postoperatively. There was no
signiﬁcant difference in group (III) compared to group (II) postoperatively. The incidence of post-
operative side effects were more in group (III).
Conclusion: Adding verapamil 2.5 mg to Lidocaine plus ketamine (0.5 mg/kg) for IVRA was effec-
tive and safe adjuvant for acute pain after surgery.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Intravenous regional anesthesia (IVRA), ﬁrst described by
August Bier in 1902, proved to be successful for short
operative procedures on the extremities performed on an
208 I.M. Esmat, D.Y. Kassimambulatory basis and is simple, reliable and cost-effective, with
success rates between 94% and 98% [1,2]. Lidocaine 0.5% is
the local anesthetic (LA) used but it has a short duration of
action after tourniquet release [3]. Disadvantages of IVRA
are LA toxicity, slow onset, poor muscle relaxation, tourniquet
pain and minimal postoperative pain relief [2]. Different agents
used as additive to local anesthetic for IVRA to avoid the dis-
advantages including phencyclidines, non-steroidal anti-
inﬂammatory drugs, opioids and muscle relaxants [2].
Nociceptive stimulation, induced by the incision and tissue
damage, causes neurotransmitter release, coupled with activa-
tion of voltage-dependent calcium conductance in synaptic ter-
minal membranes of neurons. A disruption of calcium inﬂux
into the cells interferes with normal sensory processing and
contributes to anti-nociception. Peripheral tissue injury pro-
vokes peripheral and central sensitization [4]. The actions of
excitatory amino acids are mediated by the N-methyl-D-
aspartate (NMDA) receptor and non-NMDA receptors. Acti-
vation of NMDA receptors leads to Ca2+ entry into the cell
and initiates a series of central sensitization [5]. NMDA recep-
tors are involved in decreasing postsynaptic depolarization of
unmyelinated C-ﬁbers [6]. This central sensitization could be
prevented not only with NMDA antagonists such as ketamine
and dextromethorphan, but also with calcium channel block-
ers that block Ca2+ entry into cells [7]. NMDA receptor antag-
onists are implicated in perioperative pain management as they
modulate central sensitization [8].
Ketamine, a phenyl-piperidine derivative, was ﬁrst synthe-
sized in the early 1960s and marketed as an intravenous anes-
thetic at the beginning of the seventies. At subanesthetic (i.e.,
low) doses, ketamine exerts a non-competitive blockade of
NMDA receptors [8]. Cardiovascular stimulating effects of
ketamine are prevented by prior benzodiazepines, inhaled
anesthetics, verapamil, etc. [9]. Ketamine is an effective anes-
thetic agent for IVRA at concentrations between 0.3% and
0.5%. Ketamine has effective local anesthetic properties and
provides sympathetic, sensory and motor block [10].
Omote et al. showed that spinal verapamil with Lidocaine
produced potent and prolonged pain relief with motor block
[11]. Choe et al. demonstrated that addition of verapamil to
Bupivacaine for epidural anesthesia resulted in less consump-
tion of analgesic postoperatively [7]. Capt et al. showed that
verapamil in addition to Lidocaine for brachial plexus block
prolonged onset of sensory anesthesia without any effect on
total analgesic duration [12]. Tabdar et al. demonstrated that
verapamil 2.5 mg added to 40 ml of 0.5% Lidocaine for Bier’s
block is more effective than 0.5% Lidocaine alone [13].
The effects of ketamine (3, 10 and 30 mg/kg) alone and in
combination with verapamil (10 mg/kg) on the acquisition,
consolidation and retrieval of memory using a passive avoid-
ance task in mice were studied. Ketamine signiﬁcantly inhib-
ited the acquisition and consolidation of memory at 10 and
30 mg/kg dose levels and these effects were not antagonized
by verapamil 10 mg/kg. Studies of sleeping time demonstrated
that pretreatment with verapamil 10 mg/kg increased the dura-
tion of sleeping time. The data also indicate that pretreatment
of surgical patients with verapamil may reduce the dose of
ketamine required for anesthesia [14].
In this study, our primary objective was to compare the
effects of adding two different doses (2.5 mg or 5 mg) of vera-
pamil to lidocaine ketamine (0.5 mg/kg) during IVRA to
detect a mean difference of total analgesic (pethidine)consumption compared with lidocaine with ketamine alone.
And our secondary goal was to compare the effects of adding
two different doses (2.5 mg or 5 mg) of verapamil to lidocaine
ketamine (0.5 mg/kg) during IVRA on sensory and motor
block onset times, sensory and motor block recovery times,
improvement of tourniquet pain, prolongation of ﬁrst anal-
gesic requirement time, pain score, sedation score and patient
satisfactory score compared with lidocaine with ketamine
alone.
2. Methods
This study was designed to be a randomized controlled double-
blind parallel study. The study was conducted in Ain-Shams
University Hospitals on 75 patients aged between 18 and
50 years of both sexes of ASA physical status I and II of
70–90 kg body weight and height 160–180 cm undergoing elec-
tive surgery of the hand or the forearm under Bier’s Block last-
ing one to one and half hours. The study protocol was
approved from the institutional ethical committee and written
informed consent was obtained from all the patients.
The exclusion criteria were patients not meeting the above
criteria, history of allergy to local anesthetic solution and ver-
apamil, patients with a history of signiﬁcant cardiac, renal,
hepatic or psychiatric disease, peripheral vascular or neurolog-
ical disease, a positive history of coagulopathy, sickle cell ane-
mia, patients receiving chronic analgesic therapy, patients
using antihypertensives, antiarrhythmics, or patients with sig-
niﬁcant bradycardia or hypotension.
Totally 75 patients meeting the inclusion criteria during the
preanesthetic evaluation were equally divided and were ran-
domly assigned to one of the three groups of patients for
administration of either; group (I, control group = 25
patients) received 40 ml of 0.5% Lidocaine plus ketamine
(0.5 mg/kg), group (II = 25 patients) received 40 ml of 0.5%
Lidocaine plus verapamil 2.5 mg plus ketamine (0.5 mg/kg)
or group (III = 25 patients) received 40 ml of 0.5% Lidocaine
plus verapamil 5 mg plus ketamine (0.5 mg/kg) for IVRA.
Randomization was done using computer-generated number
table of random numbers in a 1:1 ratio. The lignocaine used
in the study was 2% preservative free (lidocaine injection
2%, ROTEXMEDICA, TRITTAU – GERMANY) and nor-
mal saline (0.9%, manufactured by Otsuka company) was
added to make up the volume as required. The study drugs
were prepared by the anesthesia resident not involved in any
other part of the study.
On arrival in the operating room, standard monitoring was
used for all patients, which included 5 lead ECG, noninvasive
arterial blood pressure monitor, and pulse oximetry using
Datascope monitors. An intravenous catheter (20 G) was
inserted into a distal vein on the dorsum of the hand of the
operative extremity for injection of the local anesthetic solu-
tion and the non-operating upper limb was cannulated with
18 gauge intravenous cannula for intravenous ﬂuid infusion
(Ringer’s solution). Patients received 2 mg midazolam for
sedation.
The operating limb was then lifted for 5 min to exsan-
guinate blood and then Esmarch bandage was applied for
complete exsanguination of blood after which two tourniquets
were applied on the arm one distal to the other. Circulatory
isolation of the operative arm was conﬁrmed by inspection
of the hand and by the absence of radial pulse.
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300 mmHg. An intravenous solution of either lidocaine
2 mg/kg 0.5% plus ketamine (0.5 mg/kg) diluted with 0.9%
normal saline to a volume of 40 ml (group I), lidocaine
2 mg/kg 0.5% plus verapamil 2.5 mg plus ketamine
(0.5 mg/kg) diluted with normal saline to a volume of 40 ml
(group II), or lidocaine 2 mg/kg 0.5% plus verapamil 5 mg
plus ketamine (0.5 mg/kg) diluted with normal saline to a vol-
ume of 40 ml (group III) for IVRA was injected over 1 min in
the operating limb.
Surgery was allowed to proceed with the single tourniquet
till the patient became pain free. The second tourniquet was
inﬂated and the ﬁrst deﬂated only when the patient felt pain
before surgery was complete or when the ﬁrst tourniquet inﬂa-
tion time exceeded 30 min. The second tourniquet was deﬂated
when the surgery was complete, with total duration not
exceeding one and half hours.
The parameters recorded were time for onset of sensory
blockade, sensory block and sensory recovery time after deﬂa-
tion of tourniquets (which were assessed at 1-min interval from
the end of injection for the ﬁrst 10 min and then every 30 min
while in the postanesthesia care unit until the time of discharge
using 25 guage short bevel needle prick for median nerve at
thenar eminence, ulnar nerve at hypothenar eminence and ﬁrst
web space for radial nerve), onset of motor blockade and
motor recovery time (which were evaluated at 1-min interval
by asking the patient to ﬂex and extend his/her wrist and ﬁn-
gers). Motor blockade was considered complete when the
patient could not do any voluntary movement and incomplete
when patient could perform supination and pronation of hand.
When sensory and motor block was completed, the distal
cuff was then inﬂated to 250 mmHg followed by release of
the proximal cuff. Time to complain from the tourniquet pain
starting after tourniquet inﬂation for each patient (ﬁrst tourni-
quet pain time) and second tourniquet pain time were
recorded. Pain (tourniquet or postoperative) was assessed
using 10 cm marked visual analog scale (VAS) where zero
meant no pain and ten meant severe pain. Pain was assessed
at 30 min, 1, 2, 6 and 12 h after operation.
The rescue analgesia used was intravenous injection of
pethidine 0.5 mg/kg whenever demanded intraoperatively (for
relieving tourniquet pain) or intramuscular injection postoper-
atively if VAS was greater than 3. The total pethidine con-
sumption was recorded. Time to the ﬁrst request for
analgesic was used as an indicator of the duration of postoper-
ative analgesia from the time of local anesthetic injection.
The tourniquet was not inﬂated for more than 90 min and
was not deﬂated before 40 min of local anesthetic injection.
At the end of surgery, the tourniquet was deﬂated by repeated
inﬂation–deﬂation technique (deﬂating the tourniquet for 10 s
followed by 1 min of reinﬂation for three times).
Postoperative assessment of sedation was according to
sedation score where 0 = alert, 1 = sleepy and arousable by
verbal command, 2 = sleepy and arousable by tactile stimula-
tion and 3 = sleepy and arousable by painful stimulation.
Other parameters recorded were heart rate, mean arterial
blood pressure and arterial SpO2 intraoperatively every
15 min and 2, 6 and 12 h postoperatively. Side effects (such
as dizziness, tinnitus, restlessness, hallucinations, hypotension
and bradycardia) were also recorded. Hypotension was consid-
ered if there was 20% decrease below the baseline for mean
arterial blood pressure, and it was treated with intravenousephedrine (3–6 mg IV bolus). Bradycardia (heart rate < 55
beats/min) was treated with intravenous atropine (0.6–1 mg).
If there was a decrease in arterial SpO2 (<90%), it was treated
with oxygen through a transparent face mask.
The satisfaction score of the patient for the anesthetic tech-
nique was assessed postoperatively according to the following
numeric scale: 3 = good (no complaint from patient),
2 = moderate (minor complaint with no need for supplemen-
tal analgesics), and 1 = poor (complaint which required sup-
plemental analgesics).
2.1. Analysis of data
Using PASS 13 for sample size calculation, in a one-way
ANOVA study it was calculated that a sample size of 22
patients per group will achieve 80% power to detect a mean
difference of 50 mg in total Pethidine consumption with a
SD of 25 between the three groups using an F test with a
0.05 signiﬁcance level. 25 patients per group were intended
to be included to replace any dropouts.
Data were analyzed using SPSS 18.0 for Windows (SPSS,
Chicago, IL, USA). Analysis of variance was used to compare
quantitative parametric data with Tukey’s test as a post hoc
test. Kruskal–Wallis test was used for quantitative nonpara-
metric data. Chi square test was used for comparison of qual-
itative data. Continuous parametric data were presented as
mean ± SD, non-parametric data as median (IQR) and cate-
gorical data as number of patients. P-values of <0.05 were
considered statistically signiﬁcant.3. Results
No patient was excluded after inclusion to study. All patients
were able to complete the entire study and their data were
included in the ﬁnal analysis. The study was conducted since
March 2013 till November 2013.
There was no signiﬁcant difference in the demographic data
of the three groups as regards age, sex (male to female ratio),
weight, height, ASA physical status and the duration of sur-
gery in minutes (Table 1).
There was signiﬁcant difference in groups (II) and (III) as
compared to group I in terms of tourniquet pain tolerance
times, sensory and motor onset, sensory and motor recovery,
time for ﬁrst rescue analgesic(min), number of patients needed
intraoperative pethidine, total pethidine requirements in 12 h
(mg), satisfaction score and sedation score (p< 0.05) while
there was no signiﬁcant difference between groups (II) and
(III) about these measured variables as shown in (Table 2).
There were signiﬁcant lower recorded values in visual ana-
log scale in group (II) and group (III) in comparison with
group (I) 30 min,1, 2, 6 and 12 h postoperatively as shown in
(Table 3). Pain score was lower in group (III) compared to
group (II) 6 and 12 h postoperatively and this was not
signiﬁcant.
There was not a signiﬁcant difference in the mean heart rate
between the 3 groups intraoperatively. There was a signiﬁcant
decrease in the mean heart rate in group (II) and group (III)
compared to group (I) 2, 6 and 12 h postoperatively as shown
in (Fig. 1). Heart rate was lower in group (III) compared to
group (II) 6 and 12 h postoperatively and this was not
signiﬁcant.
Table 1 Demographic data and duration of surgery.
Variables Group (I) (n= 25) Group (II) (n= 25) Group (III) (n= 25) P-value
Age (years) 31.56 ± 4.8 30.48 ± 4.14 30.76 ± 5. 0.56
Sex (M:F) 12/13 12/13 14/11 0.49
Weight (kg) 73.2 ± 6 71.6 ± 5.6 70.7 ± 5.32 0.14
Height (cm) 168.8 ± 7.1 170.2 ± 4.5 169.5 ± 5 0.68
ASA (I/II) 18/7 20/5 19/6 0.46
Duration of surgery (min) 57.84 ± 6.62 59.8 ± 5. 6 58.81 ± 6.2 0.6
Data are presented as mean ± SD. ASA: American Society of Anesthesiologists.
P> 0.05 is considered statistically non-signiﬁcant between the 3 groups.
Table 2 Block characteristics of the studied groups.
Measured variables Group (I) (n= 25) Group (II) (n= 25) Group(III) (n= 25) P-value
First Tourniquet pain (min) 23.4 ± 2.9y 42.5 ± 2.66 46.3 ± 3 <0.001*
Second Tourniquet pain (min) 29.6 ± 4.4y 50.4 ± 2.7 51.9 ± 2.6 <0.001*
Onset of sensory block (min) 4.8 ± 1.23y 2.8 ± 0.7 2.39 ± 0.5 <0.001*
Onset of motor block (min) 12.6 ± 1.2y 9.53 ± 0.45 9 ± 0.5 <0.001*
Recovery of sensory block (min) 11.2 ± 3.3y 30. 6 ± 4.3 32.4 ± 3.5 <0.001*
Recovery of motor Block (min) 7.7 ± 1.34y 14.1 ± 1.5 14.5 ± 2. 9 <0.001*
Time for ﬁrst rescue analgesic (min) 29 ± 2.7y 212.8 ± 4.3 230.4 ± 5.5 <0.001*
Number of patients needed intraoperative pethidine 17y 6 4 <0.001*
Total pethidine requirements in 12 h (mg) 122.8 ± 7.5y 61.3 ± 7.4 57.8 ± 5.8 <0.001*
Satisfaction score 2 (1–3) y 4 (3–4) 3 (3–4) <0.001*
Sedation score 1 (0–1)y 3 (2–3) 3 (2.5–3.5) <0.001*
Values were mean ± SD or median (IQR).
* P< 0.001 was considered statistically signiﬁcant between the 3 groups.
y P< 0.001 was considered statistically signiﬁcant between group (I) and groups (II) and (III).
Table 3 Visual analog scale (VAS).
Timing of assessment
postoperatively
Group I (n= 25) Group II (n= 25) Group III (n= 25) P-value
30 min 5 (4.5–6)y 1 (0–1) 0 (0–1) <0.001*
1 h 4 (4–5)y 1 (0.5–1) 1 (0–1) <0.001*
2 h 4 (4–5)y 1 (0.5–2) 2 (1–2) <0.001*
6 h 5 (4.5–5)y 3 (2.5–3) 2 (2–3) <0.001*
12th hour 5 (3.5–6)y 3 (3–4) 3 (3–4) <0.001*
The pain score was expressed as median and IQR.
P value < 0.05 was considered signiﬁcant. * denotes signiﬁcant difference.
* P< 0.001 was considered statistically signiﬁcant between the 3 groups.
y P< 0.001 was considered statistically signiﬁcant between group I and groups II and III.
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Figure 1 The heart rate changes (beats/min). ** denotes
signiﬁcant difference. Lines are mean values and error bars are SD.
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blood pressure between the 3 groups intraoperatively. There
was a signiﬁcant decrease in the mean arterial blood pressure
in group (II) and group (III) compared to group (I) 2, 6 and
12 h postoperatively as shown in (Fig. 2). The mean arterial
blood pressure was lower in group (III) compared to group
(II) 6 and 12 h postoperatively and this was not signiﬁcant.
No signiﬁcant changes were noted in the SpO2 between the
studied groups throughout the study period (see Table 4).
4. Discussion
The use of lidocaine for IVRA block or Bier block has been the
mainstay to control perioperative pain, but it provides little to
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Figure 2 The mean arterial blood pressure (mmHg). ** denotes
signiﬁcant difference. Lines are mean values and error bars are
SD.
Table 4 Incidence of adverse effects during and after the
surgical operation among the study groups.
Adverse eﬀects Group I Group II Group III P-value
No. No. No.
Restlessness 3 0 0 0.44
Hallucinations 3 0 0 0.44
Paresthesia 1 1 6 0.037*
Tachycardia 2 0 0 0.11
Bradycardia 0 2 6 0.009*
Hypertension 2 0 0 0.11
Hypotension 0 2 6 0.009*
Nausea 1 2 6 0.04*
Vomiting 0 1 6 0.015*
Drowsiness 1 1 6 0.037*
Data are presented as number of patients. * denotes signiﬁcant
difference.
* P< 0.05 is considered statistically signiﬁcant between the 3
groups.
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release of neurotransmitters at both adrenergic and cholinergic
synapses [16]. In several studies it was tried to ﬁnd a local anes-
thesia mixture that allows relief from tourniquet pain and pro-
longed duration of analgesia after tourniquet release.
The results of the present study demonstrated that addition
of verapamil either 2.5 or 5 mg to lidocaine plus ketamine for
IVRA was accompanied by reduced tourniquet pain (lower
VAS scores) at the site of tourniquet application, delayed ﬁrst
request for tourniquet pain relief, more rapid onset and
delayed offset of sensory and motor block, delayed onset of
postoperative pain, and less postoperative consumption of
supplementary analgesia (pethidine) in 12 h with higher seda-
tion and satisfaction scores.
These results are in agreement with the ﬁndings of Tabdar
et al. who reported that the administration of verapamil 2.5 mg
added to 40 ml of 0.5% Lidocaine for Bier’s block is more
effective than 0.5% Lidocaine alone in prolonged ﬁrst and sec-
ond tourniquet pain tolerance time, faster onset of sensory
block and motor block, delayed recovery of sensory and motor
block with increased postoperative analgesia time and
decreased total analgesic consumption of Tramadol in
24 h [13].Kumar et al. also reported that the addition of 0.5 mg/kg of
body weight ketamine to lignocaine for IVRA delayed the
onset of tourniquet pain, reduced the time for onset of block,
reduced postoperative analgesic requirement and had a better
patient satisfaction [17].
Haider and Mahdi found that drug combination of keta-
mine, atracurium and lidocaine leads to rapid onset of sensory
block, motor block and lower VAS score for pain [18].
In this study, Sedation score was signiﬁcantly higher in
group (II) and group (III) than in group (I) postoperatively.
There was a signiﬁcant decrease in the mean heart rate and
the mean arterial blood pressure in group (II) and group
(III) compared to group (I) 2, 6 and 12 h postoperatively.
There were comparable differences between group (II) and
group (III) in VAS, the mean heart rate and the mean arterial
blood pressure 6 and 12 h postoperatively.
No signiﬁcant changes were noted in the SpO2 between the
studied groups throughout the study period.
There were also comparable differences between the 3
groups as regards the side effects of IVRA. Ketamine failed
to show signiﬁcant tachycardia, hypertension, restlessness
and hallucinations when given as an adjuvant in IVRA in
our study due to the fact that tourniquet was not deﬂated
before 20 min and verapamil was found to be effective in
relief of the activation symptoms of anxiety, tension and
excitement [19]. In spite of the tourniquet was not deﬂated
before 20 min, ketamine has well known hemodynamic effects
(hypertension and tachycardia) [17]. The occurrence of
bradycardia, hypotension, nausea, vomiting, drowsiness and
paresthesia were signiﬁcant in group (III) compared to groups
(I) and (II).
These results were partially consistent with the ﬁndings of
Tabdar et al. who demonstrated that verapamil 2.5 mg added
to 40 ml of 0.5% lidocaine for Bier’s block is more effective
than 0.5% lidocaine alone and stated that there was neither
hemodynamic instability nor any side effects in the study
group intraoperatively as well as postoperatively [13].
Gorgias et al. conducted a prospective randomized double-
blinded study in 45 patients undergoing hand or forearm sur-
gery under IVRA and also reported side effects of the addition
of clonidine 1 lg/kg or ketamine 0.1 mg/kg to lidocaine 0.5%
for IVRA in the form of hallucinations in 3 patients, paresthe-
sia in 3 patients, dizziness in 2 patients, and nausea in 1 patient
[20].
Kumar et al. compared the effect of dexmedetomidine and
ketamine when added to lignocaine in IVRA in 72 patients
undergoing hand surgery and mentioned that two patients
had restlessness in group lidocaine ketamine [17].
Haider and Mahdi found that bradycardia, restlessness and
muscle fasciculation had occurred and decreased by addition
of ketamine or ketamine plus atracurium for IVRA [13].
4.1. Limitations of the study
We limited our study population to patients undergoing carpal
tunnel release, excision of ganglion cysts, tenolysis and K wire
ﬁxation of radius or ulna excluding traumatic hand and wrist
operations. In addition, we limited our study to surgical proce-
dures scheduled for less than one and half hours, because
patients typically experience discomfort when a tourniquet is
required for greater than one and half hours.
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A study evaluating the effectiveness of Addition of verapamil
2.5 mg or 5 mg to lidocaine plus ketamine for IVRA to
decrease pain score 24 h after operation is planned as follow-
up research to this study. Further studies are necessary to
determine whether a lower IVRA dose of verapamil is more
effective in decreasing postoperative pain related to surgical
tissue disruption of the upper extremity with minimal side
effects.
5. Conclusion
Addition of verapamil 2.5 mg or 5 mg to lidocaine plus
ketamine for IVRA provided effective anesthesia, prolonged
postoperative analgesia and decreased postoperative analgesic
consumption. The postoperative undesirable side effects of
verapamil 5 mg e.g. bradycardia, hypotension, nausea, vomit-
ing, drowsiness and paresthesia were signiﬁcantly common.
Adding verapamil 2.5 mg to 40 ml of 0.5% Lidocaine plus
ketamine (0.5 mg/kg) for Bier’s block was effective and safe
adjuvant for acute pain after surgery.
Conﬂict of interest
None.
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